An analysis of data from the Hospital Episode Statistics over a 10-year period
ONCOLOGY
Fully funded by 
Content independently selected
-
Colorectal cancer: managing secondary bowel obstruction -
Peripheral T-cell lymphoma: bendamustine combo delivers high, durable remission ASCT further delayed progression in this phase 2 trial.
-
Nasopharynx cancer: reduced-volume IMRT similarly effective, less toxic Reduced risk for late xerostomia, hearing loss.
-
Early NSCLC: sublobar resection inferior to lobectomy for large tumors Poorer overall and cancer-specific survival confirmed in propensity-matched analysis.
-
ESMO updates treatment guidelines for gastrointestinal cancers Reflects new data for liver, pancreatic, soft tissue, and gastric cancer.
-
HPV+ oropharynx cancer: aggressive ART de-escalation shows benefit Reduced toxicity while maintaining survival outcomes.
-
DLBCL: lymphoma-related hypercalcemia linked to inferior survival The association did not apply to hyperparathyroidism-related hypercalcemia.
-
Ovarian cancer: maintenance niraparib benefits partial chemotherapy responders Post hoc analysis of phase 3 trial shows benefit regardless of BRCA status.
-
NSCLC: meta-analysis supports sex-dependent effect for immunotherapy Magnitude of survival benefit tends to favor men.
-
Lung cancer: sarcopenia common, predicts poorer survival in meta-analysis Prevalence was 43% in patients with NSCLC, 52% in those with SCLC.
-
Transperineal prostate biopsy: similar cancer detection rate, fewer complications Alternative approach promises to reduce postprocedure sepsis.
-
TNBC: induction with chemotherapy increases response to immunotherapy TONIC trial evaluated induction with irradiation, cyclophosphamide, cisplatin, and doxorubicin.
-
Dabrafenib/trametinib yields 5-year benefit in metastatic melanoma Data from the COMBI-d and COMBI-v trials.
-
European organizations strongly in favor of gender-neutral HPV vaccination HPV vaccination, testing best for preventing cervical cancer.